Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEX17 in Healthy Adult Volunteers
NCT07898306Phase 1Not yet recruiting
- Sponsor
- NorthLinks Bio
- Start
- Oct 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in respiratory virus infection (RTI) comparing HEX17 with Placebo (2 arms). Primary endpoints: Detection of HEX17 Bound to Nasal Epithelial Cells at Day 1 and Presence of HEX17 in Nasal Epithelial Cells Following Different Dosing Regimens at Day 43. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
HEX17
03
Conditions
respiratory virus infection (RTI)
Beyond the preview
Go deeper on NCT07898306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07898306.